Literature DB >> 20578265

Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction.

Brian D Juran1, Elizabeth J Atkinson, Joseph J Larson, Erik M Schlicht, Xiangdong Liu, E Jenny Heathcote, Gideon M Hirschfield, Katherine A Siminovitch, Konstantinos N Lazaridis.   

Abstract

UNLABELLED: Common genetic variants significantly influence complex diseases such as primary biliary cirrhosis (PBC). We recently reported an association between PBC and a single nucleotide polymorphism (rs231725) of the immunoreceptor gene cytotoxic T-lymphocyte antigen 4 (CTLA4). We hypothesized that PBC risk attributed to this polymorphism might be increased by propensity to an overly robust inflammatory response. Thus, we examined its potential interaction with the commonly studied -308AG promoter polymorphism (rs1800629) of the tumor necrosis factor (TNF) gene for which the variant TNF2A allele causes increased TNF production. The polymorphisms were genotyped in 866 PBC patients and 761 controls from independent US and Canadian registries; the effects of individual single nucleotide polymorphisms (SNPs) and their interaction on PBC risk was assessed by logistic regression. The reported association of PBC with the CTLA4 "A/A" genotype was replicated in the Canadian cohort and significant for PBC risk in the combined data (odds ratio [OR], 1.68; P = 0.0005). TNF2A allele frequency was elevated in PBC patients, but only reached borderline significance using the combined data (OR, 1.21; P = 0.042). Analysis showed that TNF2A carriage was significantly increased in CTLA4 "A/A" PBC patients compared with CTLA4 "A/A" controls (39.7% versus 16.5%, P = 0.0004); no apparent increase of TNF2A carriage was noted in CTLA4 "A/G" or "G/G" individuals. Finally, interaction under a logistic model was highly significant, as TNF2A carriage in combination with the CTLA4 "A/A" genotype was present in 6.5% of PBC patients, compared with 1.7% of controls (OR, 3.98; P < 0.0001).
CONCLUSION: TNF2A amplifies the CTLA4 rs231725 "A/A" genotype risk for PBC. Although the mechanisms remain unclear, the premise that deficiency in T-cell regulation resulting in an increased risk of PBC is amplified by overexpression of an important proinflammatory cytokine provides a basis for future functional studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578265      PMCID: PMC2922843          DOI: 10.1002/hep.23667

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  ICOS is essential for effective T-helper-cell responses.

Authors:  A Tafuri; A Shahinian; F Bladt; S K Yoshinaga; M Jordana; A Wakeham; L M Boucher; D Bouchard; V S Chan; G Duncan; B Odermatt; A Ho; A Itie; T Horan; J S Whoriskey; T Pawson; J M Penninger; P S Ohashi; T W Mak
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

2.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

3.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

Authors:  Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough
Journal:  Nature       Date:  2003-04-30       Impact factor: 49.962

Review 4.  CTLA-4 and tolerance: the biochemical point of view.

Authors:  Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 5.  Molecular biology of the 2-oxo-acid dehydrogenase complexes and anti-mitochondrial antibodies.

Authors:  M E Gershwin; M Rowley; P A Davis; P Leung; R Coppel; I R Mackay
Journal:  Prog Liver Dis       Date:  1992

6.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

7.  A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation.

Authors:  Mathias Mäurer; Silke Loserth; Annette Kolb-Mäurer; Anke Ponath; Stefan Wiese; Niels Kruse; Peter Rieckmann
Journal:  Immunogenetics       Date:  2002-03-12       Impact factor: 2.846

8.  A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele.

Authors:  Suzana Anjos; Audrey Nguyen; Houria Ounissi-Benkalha; Marie-Catherine Tessier; Constantin Polychronakos
Journal:  J Biol Chem       Date:  2002-09-19       Impact factor: 5.157

9.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

10.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

View more
  19 in total

Review 1.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

2.  Genetic polymorphisms in CTLA4 and SLC4A2 are differentially associated with the pathogenesis of primary biliary cirrhosis in Japanese patients.

Authors:  Yoshihiro Aiba; Minoru Nakamura; Satoru Joshita; Tatsuo Inamine; Atsumasa Komori; Kaname Yoshizawa; Takeji Umemura; Hitomi Horie; Kiyoshi Migita; Hiroshi Yatsuhashi; Makoto Nakamuta; Nobuyoshi Fukushima; Takeo Saoshiro; Shigeki Hayashi; Hiroshi Kouno; Hajime Ota; Toyokichi Muro; Yukio Watanabe; Yoko Nakamura; Toshiki Komeda; Masaaki Shimada; Naohiko Masaki; Tatsuji Komatsu; Michiyasu Yagura; Kazuhiro Sugi; Michiaki Koga; Kazuhiro Tsukamoto; Eiji Tanaka; Hiromi Ishibashi
Journal:  J Gastroenterol       Date:  2011-05-19       Impact factor: 7.527

Review 3.  Autoimmunity and environment: am I at risk?

Authors:  Daniel Smyk; Eirini I Rigopoulou; Harold Baum; Andrew K Burroughs; Diego Vergani; Dimitrios P Bogdanos
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 4.  The genetics of complex cholestatic disorders.

Authors:  Gideon M Hirschfield; Roger W Chapman; Tom H Karlsen; Frank Lammert; Konstantinos N Lazaridis; Andrew L Mason
Journal:  Gastroenterology       Date:  2013-04-10       Impact factor: 22.682

Review 5.  Genetics and epigenetics in the pathogenesis of primary biliary cholangitis.

Authors:  Satoru Joshita; Takeji Umemura; Eiji Tanaka; Masao Ota
Journal:  Clin J Gastroenterol       Date:  2017-11-20

6.  Functional variants of MIF, INFG and TFNA genes are not associated with disease susceptibility or hearing loss progression in patients with Ménière's disease.

Authors:  Irene Gázquez; Antonia Moreno; Teresa Requena; Jeff Ohmen; Sofia Santos-Perez; Ismael Aran; Andres Soto-Varela; Herminio Pérez-Garrigues; Alicia López-Nevot; Angel Batuecas; Rick A Friedman; Miguel A López-Nevot; Jose A López-Escamez
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-21       Impact factor: 2.503

Review 7.  Genome-Wide Association Studies in Primary Biliary Cirrhosis.

Authors:  Aliya F Gulamhusein; Brian D Juran; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2015-12-16       Impact factor: 6.115

8.  Tumour necrosis factor alpha (TNF-α) genetic polymorphisms and the risk of autoimmune liver disease: a meta-analysis.

Authors:  Shan Li; Xiamei Huang; Huizhi Zhong; Zhiping Chen; Qiliu Peng; Yan Deng; Xue Qin
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

9.  TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis.

Authors:  Agnieszka Kempinska-Podhorodecka; Zakera Shums; Michał Wasilewicz; Ewa Wunsch; Malgorzata Milkiewicz; Dimitrios P Bogdanos; Gary L Norman; Piotr Milkiewicz
Journal:  Clin Dev Immunol       Date:  2012-10-22

10.  The role of vitamin d in primary biliary cirrhosis: possible genetic and cell signaling mechanisms.

Authors:  Khanh Vinh Quốc L Ng; Lan Thi Hoàng Nguyễn
Journal:  Gastroenterol Res Pract       Date:  2013-03-26       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.